Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00356369 |
Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing polysaccharide vaccines induce a T-cell independent response, i.e. with no immune memory response. GSK Biologicals has developed a combined Men ACWY conjugate vaccine intended to protect against meningococcal disease due to serogroups A, C, W-135 and Y. In the vaccination phase of this study, the new MenACWY-TT conjugate vaccine will be evaluated in adolescents and adults using Mencevax™ ACWY as control. In the long-term follow-up phase (extension phase) of the study, the long-term protection offered by the new MenACWY-TT conjugate vaccine will be assessed up to five years after the vaccination in adolescents and adults using Mencevax™ ACWY as control.
This protocol posting deals with objectives & outcome measures of both the primary & extension phases.
Condition | Intervention | Phase |
---|---|---|
Meningococcal Infections |
Biological: meningococcal ACWY (vaccine) Biological: Mencevax™ ACWY |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age) |
Estimated Enrollment: | 500 |
Study Start Date: | December 2006 |
Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group A: Experimental
Subjects receiving GSK Biologicals' meningococcal vaccine 134612
|
Biological: meningococcal ACWY (vaccine)
One intramuscular dose.
|
Group B: Active Comparator
Subjects receiving Mencevax™ ACWY
|
Biological: Mencevax™ ACWY
One subcutaneous dose.
|
All subjects will have 7 blood samples taken: prior to and one month after vaccination and one, two, three, four and five years after vaccination. No new subjects will be enrolled in the extension phases of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.
Ages Eligible for Study: | 11 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Specific criteria to be checked at each study visit for the long term follow-up:
Philippines | |
GSK Clinical Trials Call Center | |
Manila, Philippines | |
Saudi Arabia | |
GSK Clinical Trials Call Center | |
Riyadh, Saudi Arabia |
Study Director: | Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK Biologicals ( Isabelle Harpigny ) |
Study ID Numbers: | 107386, 107392 (Ext: Y1), 107398 (Ext: Y2), 107402 (Ext: Y3), 107404 (Ext: Y4), 107406 (Ext: Y5) |
Study First Received: | July 25, 2006 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00356369 History of Changes |
Health Authority: | Philippines: Institutional Review Board |
Meningococcal vaccine Non-inferiority Persistence Immunogenicity |
meningococcal serogroups A, C, W & Y diseases Meningococcal A C W Y Diseases Healthy |
Bacterial Infections Meningococcal Infections Meningococcal Infection |
Healthy Gram-Negative Bacterial Infections Neisseriaceae Infections |
Bacterial Infections Meningococcal Infections Infection Gram-Negative Bacterial Infections Neisseriaceae Infections |